赵云龙;刘阳;

• 1:解放军总医院第四医学中心
• 2:解放军总医院

摘要(Abstract)：

<正>化疗是恶性肿瘤最常见的治疗方法。化疗药物通常作用于快速分裂的细胞,抑制细胞DNA合成复制、微管形成,代谢关键酶活性,直接破坏和杀伤癌细胞。近50年来,化疗虽然取得了重大进展,但是,临床上一些经循证医学研究公认为对某种肿瘤有效的化疗方案,对某些患者却毫无效果,且每个化疗方案亦只有30%～40%的患者获益。其主要原因可能为患者个体差异较大,标准化疗方案可能不适合所有人群。因此,化疗需要考虑药物、肿瘤和个体三者相互

关键词(KeyWords)： 基因;ERCC1;RRM1;TUBB3;化疗;疗效;预后

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 赵云龙;刘阳;

Email:

DOI:

参考文献(References)：

• [1]Lord RN,Brabender J,Gandara D,et al.Low ERCC1expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer[J].Clin Cancer Res,2002,8(7):2286-2291.
• [2]程颖,王杨.DNA损伤修复基因ERCC1的表达与非小细胞肺癌含铂辅助化疗方案的疗效相关[J].循证医学,2010,10(1):20-22.
• [3]Olaussen KA,Dunant A,Fouret V,et al.DNA repair by ERCC1in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].J Evidence-Based Med,2010,355(10):983-991.
• [4]蒋倩,蒋刚,王怡鑫.非小细胞肺癌ERCC1表达与铂类药物疗效相关性的荟萃分析[J].中华肿瘤防治杂志,2012,19(2):123-126,133.
• [5]陈金鸣,姚伟荣.ERCC1基因与非小细胞肺癌关系的研究进展[J].现代肿瘤医学,2014,(4):236-239.
• [6]Tiseo M,Bordi P,Bortesi B,et al.ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J].Br J Cancer,2013,108(8):1695-1703.
• [7]Postel-Vinay S,Soria JC.ERCC1 as predictor of platinum benefit in non-small-cell lung cancer[J].J Clin Oncol,2017,35(4):384-386.
• [8]Villalobos M,Czapiewski P,Reinmuth N,et al.ERCC1assessment in upfront treatment with and without cisplatin-based chemotherapy in stageⅢB/Ⅳnon-squamous non-small cell lung cancer[J],Med Oncol,2018,35(7):106.
• [9]Piljic Burazer M,Mladinov S,Capkun V,et al.The utility of thytoid transcription factor 1(TTF-1),Napsin a,excision repair cross-complementing1(ERCC1),anaplastic lymphoma kinase(ALK)and the epidermal growth factor receptor(EGFR)expression in small biopsy in prognosis of patients with lung adenocarcinoma:a retrograde single-center study from Croatia[J].Med Sci Mont,2017,22:1-9.
• [10]李喆,任清泉,刘延风,等.基于多种药物敏感基因检测在ⅢA-N2期NSCLC新辅助个体化疗中的应用价值[J].重庆医科大学学报,2018,(6):772-777.
• [11]韩靖,江俊伟,李文辉.非小细胞肺癌RRM1、ERCC1的表达及对含铂化疗方案预后的影响[J].现代诊断与治疗,2019,30(8):1305-1307.
• [12]Burazer PM,Mladinov S,Matana A,et al.Low ERCC1expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages-a single-center study[J].Diagn Pathol,2019,14(1):105.
• [13]Zhu Cuimin,Lian Xiangyao,Bi Yinghui,et al.Prognostic value of ribonucleotide reductase subunit Ml(RRM1)in nonsmall cell lung cancer:a meta-analysis[J].Clin Chim Acta,2018,485:67-73.
• [14]Besse B,Olaussen KA,Soria JC.ERCC1 and RRM1:Ready for Prime Time?[J].J Clin Oncol,2013,31(8):1050-1060.
• [15]Jordheim LP,Seve P,Tredan O,et al.The ribonucleotide reductase large subunit(RRM1)as a predictive factor in patients with cancer[J].Lancet Oncol,2011,12(7):693-702.
• [16]Belkouz A,Labeur TA,Dierks J,et al.Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer:a systematic review and meta-analysis[J].Crit Rev Oncol Hematol,2019,141:82-94.
• [17]Ren SX,Li AW,Zhou SW,et al.Individualized chemotherapy in advanced NS CLC patients based on mRNA levels of BRCA1and RRM1[J].Chin J Cancer Res,2012,24(3):226-231.
• [18]Gong W,Zhang X,Wu J,et al.RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer:a meta-analysis[J].Lung Cancer,2012,75(3):374-380.
• [19]Dong X,Hao Y,Wei Y,et al.Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1expression[J].PloS One,2014,9(3):e92320.
• [20]Tian J,Han S.Role of RRM1 in the treatment and prognosis of advanced non-small cell lung cancer[J].Chin J Lung Cancer,2015,18(6):381-386.
• [21]Zhu CM,Lian XY,Bi YH,et al.Prognostic value of ribonucleotide reductase subunit Ml(RRM1)in non-small cell lung cancer:a meta-analysis[J].Clin Chim Acta,2018,485:67-73.
• [22]Liang W,Guo M,Pan Z,et al.Association between certain nonsmall cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition[J].Cancer Sci,2019,110(6):2014-2021.
• [23] Yang YL,Luo XP,Xian L,et al.The progno stic role of the classⅢβ-tubulin in non-small cell lung cancer(NSCLC)patients receiving the taxane/vinorebine-based chemotherapy:A metaanalysis[J].PLoS One,2014,9(4):e93997.
• [24]Reiman T,Lai R,Veillard AS,et al.Cross-validation study of classⅢbeta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer:analysis of four randomized trials[J].Ann Oncol,2012,23(1):86-93.
• [25]Zhang Y,Yang H,Liu J,et al.High expression levels of classⅢβ-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy[J].Oncol Lett,2013,6(1):220-226.
• [26]尹志永,杨大勇,杨立丰,等.多种分子检测对晚期非小细胞肺癌辅助治疗的临床研究[J].临床肺科杂志,2016,21(5):947-950.
• [27]万李萍,李艳,朱洪松.肺癌患者早期个性化治疗中ER CC1和TUBB3基因联合检测的临床意义[J].医药论坛杂志,2019,40(11):79-82
• [28]Gong L,Mao W,Chen Q,et al.Analysis of SPARC and TUBB3as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy:a prospective study[J].Cancer Chemother Pharmacol,2019,83(4):639-664
• [29]Imai H,Shimizu K,Kawashima O,et al.Clinical significance of various drug-sensitivity markers in patients with surgically resected pulmonary pleomorphic carcinoma[J].Cancers(Basel),2019,11(11):E1636.
• [30]Deng LL,Deng HB,Lu CL,et al.Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma[J].Clin Transl Oncol,2019,21(2):197-205.
• [31]Levallet G,Bergot E,Antoine M,et al.High Tubb3 expression,an independent prognostic marker in patients with early nonsmall cell lung cancer treated by preoperative chemotherapy,is regulated by k-ras signaling pathway[J].Mol Cancer Ther,2012,11(5):1203-1213.
• [32]王波,王彬,张连斌,等.TUBB3/STMN1基因表达与非小细胞肺癌EGFR通路的相关性[J].中国肺癌杂志,2013(10):45-50.
• [33]Mccarroll JA,Gan PP,Erlich RB,et al.TUBB3/βⅢ-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer[J].Cancer Res,2015,75(2):415.
• [34]任保瑞,朱彦君,王桂洪,等.非小细胞肺癌EGFR,KRAS基因突变与RRM1、TUBB3 mRNA表达水平的相关性[J].现代肿瘤医学,2016,24(14):2214-2217.